Erw316

Preclinical

Novartis

Erw316 is one of 6 therapeutic programs targeting Advanced HR+/HER2- Breast Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced HR+/HER2- Breast CancerWithdrawn

Advanced HR+/HER2- Breast CancerPreclinical

Withdrawn

Competition

Competitive Landscape

6 competitors in Advanced HR+/HER2- Breast Cancer

#DrugCompanyPhaseTrials

Femara

Novartis

Phase 1

3 2

Faslodex

FFresenius Kabi Oncology Ltd.

Phase 1

4 3

Kisqali

Novartis

Preclinical

1 4

ECI830

Novartis

Preclinical

1 5

GVV858

Novartis

Preclinical

1 6

Erw316

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced HR+/HER2- Breast Cancer1 trial

An Open-label, Multi-center, Phase I/II Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Withdrawn· Novartis logo

Novartis·Preclinical·NCT07570966

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Erw316. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Erw316. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Novartis

Erw316

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Advanced HR+/HER2- Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News